AZD1613

AZD1613 is an **investigational drug** currently in early-stage clinical development. It is being studied primarily to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy volunteers. The drug is being administered both as a subcutaneous injection and as an intravenous infusion in a first-in-human, randomized, single-blind, placebo-controlled Phase 1 clinical trial. Details about the exact mechanism of action, molecular target, and therapeutic indications have not been disclosed in publicly available sources. AZD1613 is developed by AstraZeneca, and the results of these studies will inform subsequent research into its potential use for specific diseases[1][2][3][7][8][9][10].

Other names

anti-PAPPA mAbanti-PAPPA monoclonal antibodyPAPPA-1 mAbPAPPA1 mAbPAPPA 1 mAb